Pharmacy Week in Review: October 13, 2017

In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.

The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.

In adults with T2D, insulin icodec offers once-weekly therapy, reducing injection burden while providing effective glycemic control and simplified dosing.

Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.

Two recent graduates share strategies for standing out in the competitive fellowship application process.

Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.

Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.

This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.